ReciBioPharm Secures Gates Foundation Grant to Advance RNA Manufacturing

• ReciBioPharm, a division of Recipharm, received a three-year grant from the Bill & Melinda Gates Foundation to enhance RNA manufacturing technologies.

• The project aims to deploy xRNA Continuous Manufacturing technologies to low- and middle-income countries (LMICs) and develop advanced inline PAT and predictive analytics software.

ReciBioPharm, a leading Contract Development and Manufacturing Organisation (CDMO) has announced receiving a three-year grant from the Bill & Melinda Gates Foundation. The funding will support the development and deployment of xRNA Continuous Manufacturing technologies, focusing on low- and middle-income countries (LMICs). This initiative aims to improve the scalability, quality, and accessibility of RNA-based medicines globally.

The project includes developing cutting-edge inline Process Analytical Technology (PAT) and predictive analytics software. These advancements will enhance RNA manufacturing processes, helping meet the industry’s growing demand for high-quality and scalable RNA solutions.

Vikas Gupta, President of ReciBioPharm, highlighted the grant’s importance, stating: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.”

Aaron Cowley, Chief Scientific Officer of ReciBioPharm, added: “Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics. This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.”

By leveraging advanced technologies, scalable processes, and GMP standards, ReciBioPharm aims to address critical global health challenges. The grant marks a step forward in the company’s mission to integrate continuous manufacturing processes within the biomanufacturing sector and deliver innovative RNA-based solutions worldwide.